rdoe_persona_userprofile
rdoe_persona_select_up

Join this live event: Unlocking the Full Potential of AAV-Mediated Gene Delivery

Adeno-associated virus (AAV) vectors continue to be at the forefront of gene therapy innovation. Yet, despite significant advances, challenges remain in optimizing AAV-based treatments for broader clinical application.

In this Cell & Gene Live hosted by Cell & Gene's Chief Editor, Erin Harris, we are honored to host two leading experts in the field:

Sue Browne, Ph.D., Chief Development Officer at Passage Bio, and Nina Hunter, Ph.D., Vice President of Clinical Development at REGENXBIO.

viral vectors

These pioneering companies share a rich history in AAV gene therapy with roots tracing back to the groundbreaking work of Dr. James Wilson. Browne and Hunter will discuss the latest developments in AAV vector design, manufacturing processes, and clinical strategies. They will also address key issues such as immunogenicity and regulatory considerations that are shaping the future of AAV gene therapies. 

Live event sponsored by Roche CustomBiotech

December 10, 2024 
11:00 AM Eastern Standard Time